Thrombocytopenia Due to Immune Destruction has one of the most active rare disease trial programs, driven by drug treatment and biological therapy.
Recruiting
Active Trials
22 additional trials involve behavioral, dietary, diagnostic, or observational approaches.
33 trials are observational or have no phase designation.
Trials often recruit across multiple countries, so totals exceed the trial count.
Stay informed about clinical trials for Thrombocytopenia Due to Immune Destruction.
Follow this disease to get updates when trials open, close, or change status.
Already have an account? Sign in to manage your watchlists.
Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.
Last sync: March 16, 2026 at 7:14 PM